Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will release first quarter 2026 financial results after market close on Thursday, May 14, 2026. Management will host a live webcast and teleconference the same day at 4:30 p.m. Eastern Time to review results and provide a corporate update. A webcast replay will be available on the company website.
Positive
- None.
Negative
- None.
News Market Reaction – CELC
In the May 7 session, CELC declined 6.26%, reflecting a notable negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Earnings scheduling | Neutral | -1.4% | Announced Q4 and full-year 2025 results date and webcast logistics. |
| Nov 05 | Earnings scheduling | Neutral | +2.2% | Set Q3 2025 results release date and post-close webcast details. |
| Aug 07 | Earnings scheduling | Neutral | +0.1% | Scheduled Q2 2025 financial results and 4:30 p.m. ET conference call. |
| May 07 | Earnings scheduling | Neutral | +0.6% | Announced Q1 2025 results timing and investor call access numbers. |
| Mar 24 | Earnings scheduling | Neutral | +3.2% | Outlined Q4 and full-year 2024 results date and webcast/call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings/webcast dates has historically produced modest, mixed price reactions clustered around small single-day moves.
Over the past year, CELC has repeatedly issued notices scheduling its quarterly and annual results with accompanying webcasts at 4:30 p.m. ET. Prior first‑, second‑, third‑quarter and year‑end scheduling releases (from Mar 2025 through Mar 2026) led to single‑day moves between roughly -1.4% and +3.24%. These releases primarily inform investors of timing and access details rather than new financial or clinical data, and the current Q1 2026 scheduling fits that established communication pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1760785&tp_key=2f73ec65ba. A replay of the webcast will be available on the Celcuity website following the live event.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer (“ABC”), has reported detailed results for the PIK3CA wild-type cohort and topline results for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib in combination with a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with endocrine resistant HR+/HER2- ABC, is ongoing. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924
